European Group - International Society for Apheresis

Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study - Clinical Research in Cardiology Supplements Elevated lipoprotein(a) (Lp(a)) has emerged as an important independent cardiovascular risk factor, and causal association has been accepted with adverse outcome in atherosclerotic disease. Lipoprotei...

Reinhard Klingel from Apherese ForschungsInstitut - AFI | Apheresis Research Institute reporting long term follow up of #lipoprotein #apheresis at the 23rd #apheresis therapy seminar. For more details read the accompanying paper link.springer.com/article/10.1...

Vega Goedecke from #Medical School Hannover
presenting the baseline data from #EXTINCT #postcovid study to treat #MECSF / #Longcovid with #immonoadsorption. The results of this randomized controlled trial will help to answer many questions of this complex disease.

From the ice bear Knut to the bedside - Harald Prüss from @bihatcharite.bsky.social on antibody mediated encephalitis and its treatment by #apheresis.

Prof. Schmidt-Ott and Prof. Klingel opening the 23rd edition of the #apheresis therapy seminar in #Berlin.

Don’t miss arenesdelaplasma.org

Volker Schettler chairing the #apheresis session at the 17th annual meeting of the @dgfn.bsky.social.

Developing a Protocol for Therapeutic Plasma Exchange in Tandem With Continuous Renal Replacement Therapy (CRRT) and ExtraCorporeal Membrane Oxygenation (ECMO) in Pediatric Patients Therapeutic plasma exchange (TPE) in pediatric patients presents many challenges, including management of a large extracorporeal volume (ECV) and calcium replacement for patients who may not be able ...

If one is not enough: A protocol for extracorporeal triple whammy of #ECMO #CKRT and #TPE in #pediatrics published at onlinelibrary.wiley.com/doi/10.1002/...

How to treat #CDIP by #apheresis? #TPE or #IA? Find answers in a recent analysis 👍

rdcu.be/eALsf

Smart, Individualized Green Hemodiafiltration ‐ Effects of Individualized Dialysate Flow Through AutoFlow on Dialysate Consumption and Parameters of Dialysis Adequacy in the Setting of Online Hemodiafiltration Introduction High-dose online HDF compared with hemodialysis reduces all-cause mortality, but increases water consumption. We postulate that the conundrum could be solved by individualizing dialysat...

Check out the latest #TAD paper on how to safe water suring dialysis and still perform #HDF.
onlinelibrary.wiley.com/doi/10.1111/...

This is how TPE in the ICU looks like in 🇫🇷 prior to the #EXCHANGE-2 trial:
Epidemiology of Patients Treated With Plasma Exchange in a French Intensive Care Unit: An Observational Retrospective Study - Dupuis - Therapeutic Apheresis and Dialysis onlinelibrary.wiley.com/doi/full/10....

#seraph 100 to treat preeclampsia? Encouraging in vitro results by Amelie Gienapp et al.
onlinelibrary.wiley.com/doi/10.1111/...

Lipoprotein apheresis: Current overview and future outlook in clinical practice Lipoprotein apheresis (LA) remains a critical therapeutic approach for patients with severe lipid disorders, particularly those who fail to achieve ta…

Is there a future of lipoprotein apheresis? Read the latest paper by Prof. Schettler www.sciencedirect.com/science/arti...

The number of apheresis procedures to treat immune-mediated neurological diseases is on the rise Apheresis is used for the treatment of many different diseases, especially when conventional therapy lacks efficacy. There are however some diseases in which apheresis is accepted as first line therap...

New data from the World apheresis registry show an increase in #apheresis procedures for neurological diseases. While the total number of procedures did not increase #myasthenia gravis, #Guillain-Barré Syndrome, #multiple sclerosis, #CIDP and #NMOSD were on the rise.
www.trasci.com/article/S147...

Effect of therapeutic plasma exchange on amoxicillin, clindamycin, midazolam, and morphine pharmacokinetics in a critically ill child - Pediatric Nephrology We report a 15-year-old boy with severe septic shock and multiple organ failure, requiring intensive care and extracorporeal therapies, including veno-arterial extracorporeal membrane oxygenation, con...

How to dose drugs in a patient undergoing the extracorporeal triple whammy of #VA-ECMO #CVVHDF and #TPE? An anecdotal answer given in: link.springer.com/article/10.1...

#Apheresis Classics:
1541 citations so far for the seminal paper by Gail Rock et al. Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura | New England Journal of Medicine www.nejm.org/doi/full/10....

E-ISFA Regional 👍

Ken Yamaji (ISFA outgoing president) and Kriengsak Vareesangthip (congress president) hand over the flag of #ISFA to Rasheed Balogun (ISFA incoming president) and Amber Sanchez #ISFA congress president 2027. See you in San Diego.

Apheresis Equipment Market Projected to Reach USD 5 Billion by 2034, Growing at a CAGR of 7.00% The global apheresis equipment market was valued at USD 2.5 billion in 2024 and is expected to grow at a CAGR of 7.0% from 2025 to 2034. The market is driven by growing applications in therapeutic plasma exchange and blood component separation. Market Definition The Apheresis Equipment Market revolves around medical devices that perform extracorporeal blood separation to collect or remove specific components—such as plasma, platelets, red cells, leukocytes, or stem cells—returning the remaining blood back to the donor or patient. These systems utilize technologies like centrifugation and membrane filtration to support applications across blood donation centers, hospitals, and therapeutic settings—such as leukapheresis, plasmapheresis, stem cell harvesting, and therapeutic plasma exchange (TPE).

Apheresis Equipment Market Projected to Reach USD 5 Billion by 2034, Growing at a CAGR of 7.00%

The global apheresis equipment market was valued at USD 2.5 billion in 2024 and is expected to grow at a CAGR of 7.0% from 2025 to 2034. The market is driven by growing applications in therapeutic…

Starting day #3 of #ISFA 2025 with talks on rhabdomyolysis and ascites management.

Turn back the clock by #TPE or just another variation to the theme of midlife crisis?
Dobri Kiprov is showing that makers of the epigenetic clock are improved after #TPE. An expensive sip from the fountain of youth.

From bed (or in this case PET) to bench - cutting edge research on the effect of Lipoprotein(a) on cardiovascular pathophysiology by @kroonlab.bsky.social at #ISFA 2025.

#photopheresis nicely explained by Jennifer Schneiderman #ISFA 2025.

@tusharchopra.bsky.social summarizing the current status of #green #apheresis at #ISFA 2025. Everybody can implement small steps today!

Laying the foundation of what could be #TPE-MBD (therapeutic plasma exchange associated bone mineral disease) Amber P. Sanchez from @ucsdmedschool.bsky.social with new data on bone markers in #apheresis patients showing an impressive rise in #PTH.

Kornchanok Vareesangthip setting the stage to discuss findings in a national cohort of #apheresis patients.

One world different regulations - Daisuke Katagiri explaining techniques and reimbursement of apheresis in Japan.

Starting day #2 of #ISFA 2025 with a comparison of mTPE and cTPE by Mickael Beraud.

Comparing #TPE and #IA in the setting steroid refractory #MS - Johannes Drost.

Still unavailable in many industrialized countries - excellent overview of #immunoadsorption by Bernd Hohenstein.

Is there a future for lipid apheresis after the advent of pharmaceutical options to lower LDL-C and Lp(a)?
Provocative talk by Wolfgang Ramlow showing a remarkably low target attainment in a real life setting at #ISFA2025.